LYNOZYFIC
Launchlinvoseltamab-gcpt
BLAINJECTIONSOLUTIONPriority Review
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
LYNOZYFIC (linvoseltamab-gcpt) is linvoseltamab-gcpt is a bispecific t-cell engaging antibody that binds to the cd3 receptor expressed on the surface of t-cells and b-cell maturation antigen (bcma) expressed on the surface of multiple myeloma cells and some healthy b-lineage cells. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNOZYFIC (linvoseltamab-gcpt) is a bispecific T-cell engaging antibody approved July 2, 2025, for multiple myeloma. It binds CD3 on T-cells and BCMA on myeloma cells, bridging immune activation to tumor lysis. The mechanism leverages T-cell cytotoxicity to target BCMA-expressing malignancies.
Growth
Early-stage launch product in a high-stakes oncology segment with moderate competitive pressure; commercial team buildout and market penetration strategies are active priorities.
Mechanism of Action
Linvoseltamab-gcpt is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, linvoseltamab-gcpt activated T-cells,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LYNOZYFIC represents a career opportunity in a newly launched, innovative bispecific oncology therapy with significant unmet need in multiple myeloma. Join a high-growth commercial team navigating a competitive landscape, managed care negotiations, and complex patient support infrastructure for a premium-priced biologic therapy.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.